please read the link. you will find that cfs is really poorly understood, little studied, and there are no estimates that are scientific for actual incidence.
if the estimate is 16% are diagnosed of the est. 500k, then you have a patient population of about 80k, with only a portion being severely debilitated. i would think the target population would wind up about half of that. if the drug is used by half the target, then you have a usage in 20,000 patients. if treatment is given in a a year to half of that group, you have 10,000 patients per year on the drug.
feel free to offer a different interpretation. but at least try to back it up with some reasonable thinking and assumptions.
ampligen is not a pill, its a very invasive treatment, akin to chemotherapy. many patients will choose not to undergo it. as is the case with all intravenous treatments. drug companies try like hell to avoid intravenous treatments for non-fatal diseases.
and interestingly, cfs apparently runs its eventual course over 7 years.